Latest Conference Articles

Clinicians can use the MSPT, an iPad-based neurological performance test that simulates and extends the Multiple Sclerosis Functional Composite, to measure motor and visual function in patients with multiple sclerosis.

Acid reduction from PPI treatment may alter bacterial flora in the digestive system, which may increase an individual's susceptibility to infection.

Shortening IFN-free combination treatment of chronic HCV to 16 weeks and eliminating the induction dose of deleobuvir reduces viral load and treatment-induced side effects, according to a recent clinical trial.

Study results show that patients treated with Stribild had significantly reduced viral load and increased CD4 counts after 96 weeks, with fewer patients discontinuing treatment due to side effects.

Patients with relapsing-remitting multiple sclerosis treated for two years with alemtuzumab demonstrated improved disease-related disability scores compared to patients who received treatment with subcutaneous interferon beta-1a.

Study results show that hip flexion weakness and, to a lesser extent, ankle dorsiflexion weakness have the greatest impact upon changes in walking speed as MS progresses

Data indicate patients with relapsing remitting multiple sclerosis (RRMS) treated with BG-12 (dimethyl fumarate) showed no clinical disease activity for up to two years.

Implementation of computerized customized order entry sets in a large urban hospital reduced HIV medication error rates by more than 35%.

Study finds men with HIV and chronic HCV infection are more likely to receive treatment than women. The same study also indicates Caucasians with HIV and HCV co-infection are more likely to receive treatment than their African-American counterparts.

Researchers reported the MMRV and separately administered MMR plus varicella vaccines were associated with a greater incidence of fever, seizures, and immune thrombocytopenia purpura seven to 10 days after vaccine administration.

Study finds there are often long delays between diagnosis and referral for treatment by a specialist for patients with hepatitis C, and also long delays from the time of referral to initiation of treatment.

The bias toward traditional care models is slowly eroding, with greater numbers of primary care providers (especially physicians) becoming aware of the advantages to a more collaborative approach to care that invites greater contributions from NPs, PAs, and other providers.

Update on treatment planning, risk management, and ongoing monitoring for efficacy, safety, and adherence in patients treated with opioids for chronic, noncancer pain.

Group visits can be an especially effective tool for providing follow-up care to patients with chronic conditions, offering them increased access to clinicians and other providers, support and encouragement from their peers, and enhanced educational opportunities.

News and updates about IDWeek 2013.

Studies have shown that plasticizers such as BPA and phthalates and other potential endocrine disruptive chemicals can have harmful effects and may be contributing to several ongoing public health concerns.

The increasing incidence of C. difficile infection in hospitals and other settings, coupled with the emergence of new high-virulence strains, requires physicians to understand the risk factors associated with this condition and be prepared to effectively diagnose and manage it.

Primary care physicians should be aware of the signs and symptoms of common liver conditions, and incorporate the latest laboratory tests and diagnostic procedures into practice.

A solid history and physical exam, several quick tests to localize pain, and a management plan that incorporates physical therapy can produce good outcomes without resorting to surgery.

Early diagnosis by primary care physicians and aggressive treatment are essential to slowing the epidemic of kidney and cardiovascular disease.

Primary care physicians should use proven risk estimation models, genetic counseling, and other tools to identify high-risk patients, and then engage patients in shared decision making to identify the best options for prevention.

News and updates about Pri-Med East 2013.

Recently released testing guidelines and expanded access to insurance coverage under the ACA may improve awareness and treatment among HIV-positive, economically underserved, and minority populations that are disproportionately impacted by viral hepatitis infection.

Study results presented at the 2013 United States Conference on AIDS show that both combo drugs have a similar efficacy profile in ART-naïve patients, but patients treated with Complera reported fewer and less severe side effects.

Researchers found that overall cognitive performance was below average in a sample of patients with HIV who were referred for neurocognitive evaluation. Especially affected were areas involving memory, which can have a negative effect on treatment adherence.

Increased spending for treatment of HIV patients does not necessarily lead to a more positive clinical outcome, according to a new study presented at the 2013 United States Conference on AIDS.

By providing HIV testing, counseling, screening for other STDs, transportation assistance, and other services, these programs were able to successfully identify new cases of HIV in high-risk groups and provide them with follow-up care.

In addition to recommending antiretroviral therapy for all HIV-infected individuals to reduce the risk of disease progression, the revised document also offers guidance on initial treatment regimens, early HIV infection, drug-resistance testing, and more.

Study shows patients who switched from treatment with a ritonavir-boosted protease inhibitor maintained virologic suppression, experienced improved lipid profiles, and suffered fewer side effects.

New insurance protections, changes in how AIDS Drug Assistance Program benefits are counted, Medicaid expansion, and other provisions in the law will mean better care for many patients.